Lenvima (Lenvatinib): The 2027-2030 Generic Opportunity Window

Eisai and Merck's blockbuster receptor tyrosine kinase inhibitor Lenvima (lenvatinib mesylate) generated JPY 328.5 billion (approximately $2.26 billion) in full-year global sales, with U.S. annual net revenues exceeding $1.2 billion and Merck reporting $1.01 billion in alliance revenue. No generic lenvatinib is approved or commercially sold in the United States today, maintaining a 100% brand-only market. Core crystalline salt polymorph patent US 7,612,208 ('Crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide') expires on March 19, 2027, inclusive of a six-month pediatric exclusivity extension granted under Section 505A of the FD&C Act. While high-purity substance patent US 11,186,547 extends to February 2036, leading Indian generic manufacturers including Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Torrent Pharmaceuticals have resolved Hatch-Waxman Paragraph IV patent litigation through confidential settlements granting licensed generic entry beginning July 1, 2030. Separately, generic challenger Shilpa Medicare was enjoined in federal district court through February 2036. This multi-billion dollar oncology franchise represents a major generic opportunity window approaching the March 19, 2027 statutory milestone and July 1, 2030 licensed market entry.